Heron Therapeutics Launches New Private Infrastructure Investment Strategy for Enhanced Portfolio Diversification

Heron Therapeutics Expands Investment Portfolio with New Private Infrastructure Strategy

Heron Therapeutics announces the launch of a private infrastructure investing strategy aimed at accredited individual investors and family offices. This innovative initiative allows investors to access a diversified portfolio of over 1,000 infrastructure assets, which include sectors such as power generation, transportation, telecommunications, and digital infrastructure. By connecting investors with five seasoned fund managers, Heron enhances its platform that previously focused on private credit and private equity. CEO Mike Sall emphasizes that this expansion enriches investment opportunities for clients seeking to achieve long-term returns while protecting their portfolios against inflation.

The new private infrastructure strategy showcases promising performance, boasting an average annualized return of 13.5% after fees since inception. This figure is significant, especially in the context of an economic landscape marked by volatility and inflationary pressures. The fund managers involved bring over 20 years of experience in managing private infrastructure funds, which adds a layer of expertise to the investment offerings. By employing a proprietary fund scoring process, Heron not only selects high-performing funds but also indicates the potential for future additions to this growing strategy, ultimately broadening the scope of alternative investment options available to clients.

Heron's commitment to diversifying investments extends to the historical resilience of private infrastructure as an asset class. The company highlights that infrastructure investments tend to hold strong during economic downturns and inflationary periods. With projections indicating that 2026 could be pivotal for private infrastructure investments—driven by growth in sectors like power generation and logistics—Heron's strategy positions itself as a timely and strategic avenue for investors. The initiative not only complements existing offerings but also aims to capitalize on the anticipated demand for robust, inflation-hedged investments.

In addition to the new infrastructure strategy, Heron Therapeutics continues to engage with investors through its proprietary ranking process, ensuring a focus on quality and performance in its fund selections. The company’s expansion into private infrastructure reflects a broader trend within the investment landscape, where individuals seek to diversify their portfolios beyond traditional public markets.

For those interested in understanding the potential of private infrastructure investments, the article "Why invest in private infrastructure in 2026? 3 charts for investors" provides valuable insights into the advantages of this asset class, showing how it can serve as a strategic hedge in uncertain economic climates.